Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14268141 | 0.84 | GABRA1 (0.48) | CA2ATMKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL19578912 | 0.83 | PTGS2 (0.52) | CA2PTGS2TUBB1GAAATM | |
| SCHEMBL7934262 | 0.82 | KDM4E (0.48) | CA2GAAATMKDM4EALDH1A1 | |
| SCHEMBL2723044 | 0.82 | CA2 (0.45) | CA2GAAATMKDM4EHTT | |
| SCHEMBL31428 | 0.80 | CA2 (0.71) | CA2PTGS2ATMKDM4EHTT | |
| SCHEMBL31275634 | 0.80 | CA2 (0.71) | CA2PTGS2ATMKDM4EHTT | |
| SCHEMBL22228111 | 0.79 | CYP1A2 (0.46) | CA2TUBB1GAAATMKDM4E | |
| Ammonia Solution, Strong SCHEMBL266403 | 0.78 | CA2 (0.68) | CA2PTGS2ATMKDM4EHTT | |
| SCHEMBL8940769 | 0.78 | HTR7 (0.53) | CA2PTGS2TUBB1GAAATM | |
| Water SCHEMBL8587595 | 0.78 | CA2 (0.68) | CA2PTGS2ATMKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737811-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-10 | — | — | EP | disclosed |
| US-8193365-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100249024-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7737295-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1737811-A4 | CETP INHIBITORS | MERCK & CO INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| CN-1942428-A | CETP inhibitors | MERCK & CO INC (US) | 2007-04-04 | — | — | CN | disclosed |
| EP-1737811-A1 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100298-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | CA2 4358/4885PTGS2 2744/4885TUBB1 2435/4885 |
| US-20100249024-A1 | CETP INHIBITORS | CETP, APOB, NPC1 | CA2 4358/4885PTGS2 2744/4885TUBB1 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.